#London #United Kingdom #Urology #Esaote #PAM Technology

Esaote Unveils Innovative Technology at EAU 2026

The Esaote Group, a leading Italian innovator in the field of medical imaging, unveiled its groundbreaking Prostate Attention Map (PAM) technology at the annual European Association of Urology (EAU) Congress held in London from March 13 to 16, 2026. This new entrant in the realm of urological diagnostics promises to elevate the accuracy and efficiency of imaging procedures significantly.

At its exhibit (booth N16), Esaote presented the PAM technology integrated into the new MyLab™E85 GTS Edition, which aims to enhance the precision of urological imaging. Alongside this, the company introduced the MyLab™C30 GTS, a portable ultrasound system that delivers high-quality imaging across various examination environments.

The PAM technology stands out by offering automatic analysis of multiparametric MRI (mpMRI) prostate volumes, pinpointing regions that may require further investigation. This innovative feature is designed to assist urologists in optimizing target guidance and decision-making during procedures. According to Marta Daniel, Director of Guided Therapy and Clinical Solutions at Esaote, "The PAM technology is fully integrated within Esaote’s UroFusion software. Our UroFusion package is tailored to provide focal guidance during prostate biopsies. Thanks to AI integration, urologists can experience a streamlined workflow akin to a standard biopsy while enhancing their confidence and precision throughout the procedures."

During the congress, Esaote was actively involved in practical sessions focused on transperineal biopsy and MRI-ultrasound fusion techniques. These sessions were led by internationally recognized specialists, enabling attendees to experience the latest advancements in UroFusion firsthand. The introduction of PAM technology, coupled with the new ultrasound systems, indicates a significant expansion of Esaote's Guided Therapy Solutions (GTS) line, showcasing the company's commitment to empowering urologists with intelligent, reliable imaging solutions that facilitate advanced image quality and seamless workflows.

Esaote's presence at EAU 2026 reflects its ongoing dedication to improving prostate care through innovative imaging technology. The company employs over 1,300 individuals globally, with a substantial portion working in Italy. With its research and production facilities located in Genoa and Florence, as well as additional units in the Netherlands, Esaote has established a strong worldwide presence, serving over 100 countries.

In summary, the launch of the PAM technology at the EAU Congress is a testament to Esaote's innovative spirit and its drive to enhance diagnostic capabilities in urology. As the medical landscape continues to evolve, Essaote's commitment to quality and intelligence in imaging technologies positions them as a pivotal player in the advancement of urological care.